William J.  Peters net worth and biography

William Peters Biography and Net Worth

Bill Peters has served as our Chief Financial Officer, Treasurer since April 2014,  and President of International Medication Systems, Ltd. since March 2016 (Amphastar’s subsidiary). Mr. Peters previously served as Executive Vice President and Chief Financial Officer of Hi-Tech Pharmacal Co., Inc., or Hi-Tech, from August 2013 to April 2014 and Vice President and Chief Financial Officer at Hi-Tech from May 2004 to August 2013. From September 2003 to May 2004 he was Vice President of Corporate Development at Hi-Tech. From 2001 to 2003 Mr. Peters was the Director, Financial Evaluations for the Medco Health Solution subsidiary of Merck & Co., Inc., or Merck & Co., and Manager of Corporate Financial Analysis and Pharmaceutical Economics at Merck & Co. from 1998 to 2001. During his seven year career at Merck & Co., he also served as Manager of Treasury Planning and Analysis. He began his career in General Electric’s Financial Management Program at its Aerospace division, where he later held positions in financial analysis and internal auditing. He earned an M.B.A. from Wharton School of Business, University of Pennsylvania and a B.S. in Business Administration from Bucknell University.

What is William J. Peters' net worth?

The estimated net worth of William J. Peters is at least $4.37 million as of September 6th, 2023. Mr. Peters owns 101,360 shares of Amphastar Pharmaceuticals stock worth more than $4,365,575 as of May 21st. This net worth evaluation does not reflect any other assets that Mr. Peters may own. Additionally, Mr. Peters receives an annual salary of $1,120,000.00 as CFO at Amphastar Pharmaceuticals. Learn More about William J. Peters' net worth.

How old is William J. Peters?

Mr. Peters is currently 56 years old. There are 4 older executives and no younger executives at Amphastar Pharmaceuticals. The oldest executive at Amphastar Pharmaceuticals is Dr. Yongfeng Zhang Ph.D., Co-Founder, President, CEO, Chief Scientific Officer & Director, who is 77 years old. Learn More on William J. Peters' age.

What is William J. Peters' salary?

As the CFO of Amphastar Pharmaceuticals, Inc., Mr. Peters earns $1,120,000.00 per year. There are 2 executives that earn more than Mr. Peters. The highest earning executive at Amphastar Pharmaceuticals is Dr. Yongfeng Zhang Ph.D., Co-Founder, President, CEO, Chief Scientific Officer & Director, who commands a salary of $2,130,000.00 per year. Learn More on William J. Peters' salary.

How do I contact William J. Peters?

The corporate mailing address for Mr. Peters and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on William J. Peters' contact information.

Has William J. Peters been buying or selling shares of Amphastar Pharmaceuticals?

William J. Peters has not been actively trading shares of Amphastar Pharmaceuticals during the last quarter. Most recently, William J. Peters sold 60,743 shares of the business's stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a transaction totalling $3,143,450.25. Following the completion of the sale, the chief financial officer now directly owns 101,360 shares of the company's stock, valued at $5,245,380. Learn More on William J. Peters' trading history.

Who are Amphastar Pharmaceuticals' active insiders?

Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amphastar Pharmaceuticals?

In the last year, insiders at the sold shares 24 times. They sold a total of 477,225 shares worth more than $25,928,148.75. The most recent insider tranaction occured on May, 1st when Director Floyd F Petersen sold 500 shares worth more than $20,835.00. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.

Information on this page was last updated on 5/1/2024.

William J. Peters Insider Trading History at Amphastar Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/6/2023Sell60,743$51.75$3,143,450.25101,360View SEC Filing Icon  
6/15/2023Sell36,868$50.85$1,874,737.80105,603View SEC Filing Icon  
6/2/2023Sell11,000$46.35$509,850.00105,603View SEC Filing Icon  
5/18/2023Sell10,500$44.35$465,675.00105,148View SEC Filing Icon  
4/17/2023Sell5,632$42.35$238,515.20105,148View SEC Filing Icon  
4/13/2023Sell4,868$42.35$206,159.80105,148View SEC Filing Icon  
4/10/2023Sell10,032$40.35$404,791.20105,148View SEC Filing Icon  
3/15/2023Sell12,776$36.43$465,429.68118,451View SEC Filing Icon  
8/9/2022Sell10,000$38.35$383,500.00100,480View SEC Filing Icon  
6/30/2022Sell18,386$34.95$642,590.70100,480View SEC Filing Icon  
6/17/2022Sell5,512$32.05$176,659.60100,480View SEC Filing Icon  
3/15/2022Sell7,900$34.46$272,234.00View SEC Filing Icon  
2/8/2022Sell10,000$26.95$269,500.00View SEC Filing Icon  
1/10/2022Sell16,000$25.40$406,400.00View SEC Filing Icon  
1/7/2022Sell31,776$24.43$776,287.68View SEC Filing Icon  
12/21/2021Sell8,256$22.40$184,934.40View SEC Filing Icon  
12/16/2021Sell1,744$22.40$39,065.60View SEC Filing Icon  
11/11/2021Sell10,000$21.33$213,300.00View SEC Filing Icon  
7/7/2021Sell10,000$20.37$203,700.00View SEC Filing Icon  
3/15/2021Sell4,244$19.03$80,763.3285,304View SEC Filing Icon  
1/19/2021Sell6,495$18.67$121,261.65View SEC Filing Icon  
8/14/2020Sell5,512$20.36$112,224.3295,652View SEC Filing Icon  
7/6/2020Sell13,656$22.00$300,432.00View SEC Filing Icon  
3/13/2020Sell4,701$13.94$65,531.9476,011View SEC Filing Icon  
1/21/2020Sell3,990$20.07$80,079.30View SEC Filing Icon  
9/16/2019Sell9,800$21.76$213,248.0092,253View SEC Filing Icon  
8/15/2019Sell4,942$21.00$103,782.00View SEC Filing Icon  
3/4/2019Sell1,500$25.36$38,040.0077,050View SEC Filing Icon  
2/15/2019Sell10,016$24.37$244,089.9285,566View SEC Filing Icon  
1/2/2019Sell3,245$19.52$63,342.4075,550View SEC Filing Icon  
12/3/2018Sell10,000$22.40$224,000.00133,381View SEC Filing Icon  
11/12/2018Sell38,484$20.74$798,158.16106,636View SEC Filing Icon  
11/9/2018Sell10,000$21.47$214,700.00106,636View SEC Filing Icon  
8/16/2018Sell2,407$17.59$42,339.1386,836View SEC Filing Icon  
7/9/2018Sell3,250$16.46$53,495.00View SEC Filing Icon  
3/13/2018Sell19,801$20.10$398,000.10View SEC Filing Icon  
12/1/2017Sell6,226$19.67$122,465.42View SEC Filing Icon  
10/13/2017Sell3,026$18.56$56,162.56View SEC Filing Icon  
8/12/2016Sell1,027$18.19$18,681.1363,625View SEC Filing Icon  
7/18/2016Sell2,297$17.76$40,794.7264,652View SEC Filing Icon  
6/2/2016Sell2,297$16.00$36,752.0066,949View SEC Filing Icon  
See Full Table

William J. Peters Buying and Selling Activity at Amphastar Pharmaceuticals

This chart shows William J Peters's buying and selling at Amphastar Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $43.07
Low: $42.89
High: $43.95

50 Day Range

MA: $42.14
Low: $38.65
High: $44.57

2 Week Range

Now: $43.07
Low: $38.43
High: $67.66


269,722 shs

Average Volume

354,874 shs

Market Capitalization

$2.11 billion

P/E Ratio


Dividend Yield